Syra Health Corp. Class A (SYRA) AI Stock Analysis

Syra Health Corp. Class A

(Other OTC:SYRA)

Select Model

Rating:57Neutral

Price Target:$0.93▲(3.56% Upside)

Action:reiterated

Date:10/31/26

The score is primarily supported by improving financial performance and a favorable position above key moving averages. Thin profitability, weak and historically volatile cash flow, and a high P/E ratio materially constrain the overall rating.

Positive Factors

Revenue and profitability turnaroundThe sharp TTM revenue increase and return to profitability indicate meaningful operating improvement and stronger market traction. If this progress persists, expanding revenue can provide a broader base for fixed-cost absorption, reinvestment, and more durable earnings over the next several quarters.

Negative Factors

Thin operating profitabilityVery narrow margins leave limited room for cost increases, execution setbacks, or slower revenue growth before earnings are pressured. Although the company has returned to profit, the small cushion means profitability may remain fragile until scale and improved unit economics produce more consistent operating leverage.

Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $10.75M
Dividend Yield: ―
Average Volume (3M): 24.66K
Price to Earnings (P/E): 100.0
Beta (1Y): 1.45
Revenue Growth: 0.32%
EPS Growth: ―
Country: US
Employees: 89
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Syra Health Corp. Class A Business Overview & Revenue Model

Company Description

Syra Health Corp. is a U.S.-based healthcare services company offering a diverse portfolio of solutions. Their core offerings span health education, population health management, behavioral and mental health support, healthcare workforce solutions, a...

How the Company Makes Money

Syra Health generates revenue primarily by providing healthcare-related services to organizations (such as healthcare providers, employers, and public-sector entities) under contracted engagements. Key revenue streams include (1) service fees from st...

Syra Health Corp. Class A Earnings Call Summary

Earnings Call Date:May 07, 2025(Q1-2025)|% Change Since:1011.11%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentNeutral

The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.

Positive Updates

Revenue Growth

Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.

Negative Updates

Delisting from NASDAQ

The company announced a strategic decision to voluntarily delist from the NASDAQ capital market to reduce costs and strengthen core fundamentals.

Company Guidance

During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.

Syra Health Corp. Class A Financial Statement Overview

Summary

Improving profitability, margins, equity, and leverage support the score, but thin earnings, modest cash generation, and historically volatile results remain significant risks.

Income Statement

62Positive

Balance Sheet

71Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.09M	7.23M	7.98M	5.52M	5.62M	1.41M
Gross Profit	3.18M	2.49M	1.65M	1.41M	1.06M	430.35K
EBITDA	146.26K	-862.60K	-3.68M	-2.84M	-2.07M	-3,073
Net Income	130.75K	-896.33K	-3.76M	-2.94M	-2.12M	-3,280
Balance Sheet
Total Assets	3.83M	2.77M	3.68M	4.92M	2.32M	536.89K
Cash, Cash Equivalents and Short-Term Investments	2.12M	1.61M	2.40M	3.28M	3,344	100.01K
Total Debt	149.34K	143.79K	452.08K	248.10K	934.84K	342.86K
Total Liabilities	1.20M	674.74K	800.76K	910.07K	1.61M	544.04K
Stockholders Equity	2.63M	2.10M	2.88M	4.01M	710.10K	-7,147
Cash Flow
Free Cash Flow	109.58K	-447.85K	-2.94M	-2.77M	-2.37M	-94.49K
Operating Cash Flow	109.68K	-447.75K	-2.93M	-2.76M	-2.24M	-88.20K
Investing Cash Flow	-107	-107	-11.11K	-15.25K	-121.26K	-6,289
Financing Cash Flow	-291.75K	-332.82K	2.06M	6.05M	2.27M	191.50K

Syra Health Corp. Class A Technical Analysis

Technical Analysis SentimentPositive

Last Price0.90

Price Trends

50DMA0.87Positive

100DMA0.78Positive

200DMA0.52Positive

Market Momentum

MACD-0.00Negative

RSI54.36Neutral

STOCH60.08Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.90 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.87, and above the 200-day MA of 0.52, indicating a bullish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 54.36 is Neutral, neither overbought nor oversold. The STOCH value of 60.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.

Syra Health Corp. Class A Risk Analysis

Syra Health Corp. Class A disclosed 49 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Syra Health Corp. Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SYRA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CON	77Outperform	$5.15B	26.05	47.30%	0.62%	14.02%	31.92%
SGRY	59Neutral	$2.99B	-33.64	-5.21%	―	3.99%	51.58%
SYRA	57Neutral	$12.78M	100.00	5.62%	―	0.32%	―
USPH	52Neutral	$1.28B	504.88	-1.27%	2.13%	11.32%	-92.59%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DCGO	43Neutral	$24.44M	-0.13	-115.58%	―	-32.40%	-969.05%
AIRS	41Neutral	$124.72M	-9.53	-12.52%	―	-8.71%	26.89%

* Healthcare Sector Average

Performance Comparison

SYRA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SYRA	Syra Health Corp. Class A	0.90	0.83	1167.61%
USPH	U.s. Physical Therapy	85.83	1.09	1.28%
SGRY	Surgery Partners Inc.	23.21	1.51	6.96%
DCGO	DocGo, Inc.	0.25	-0.78	-76.12%
AIRS	Airsculpt Technologies, Inc.	1.73	-8.66	-83.35%
CON	Concentra Group Holdings Parent, Inc.	40.38	20.90	107.26%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Syra Health Corp. Class A AI Stock Analysis